Article Sidebar
Views PDF: 155
RESULTS OF CONCURRENT CHEMORADIOTHERAPY WITH ETOPOSIDE - CISPLATIN REGIMEN AND INTENSITY MODULATE RADIATION IN STAGE III NON - SMALL CELL LUNG CANCER
Main Article Content
Abstract
Objectives: To evaluate the treatment results of EP regimen combined with dose-modulated radiotherapy in stage III non-small cell lung cancer and describe some undesirable effects of the treatment regimen. Patients and methods: 37 patients with stage III NSCLC who received chemotherapy and radiotherapy concurrently with intensity modulated radiation therapy and etoposide-cisplatin chemotherapy regimen at K Hospital from January 2019 to June 2021. Results: Study group characteristics: Mean age 57, men account for 86,5%, selected patients were in good performance status with 22 (59,5%) in 37 ECOG 0 patients. Stage host disease mainly stage IIIB accounts for 62.2%, histopathology is mainly adenocarcinoma 64.9%. Treatment results: Evaluation of response according to RECIST 1.1 showed that the rate of complete and partial response was 2,7% and 83,8%, respectively. Progression-free survival was 14 ± 3,7 months. Progression-free survival at 12 months 54,7% was Toxicity: There were 24,3% pneumonia patients, 44,2% esophagitis patients only grade I, II. Toxicity on hematopoietic system mainly grade I, II., only 2.7% of patients appeared grade III. Toxicity on liver, kidney, vomiting, fatigue, weight loss are at 1-2 levels. Conclusion: The regimen not only gave good results in terms of response rates and progression-free survival, but also significantly reduced radiation-related toxicity
Article Details
Keywords
Lung cancer, concurrent chemoradiotherapy, EP, response rate, toxicity
References
2. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/jnci/djr325
3. Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Annals of Oncology. 2017;28(4):777-783. doi:10.1093/annonc/mdx009
4. Boyle J, Ackerson B, Gu L, Kelsey CR. Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer. Adv Radiat Oncol. 2017;2(1):6-11. doi:10.1016/j.adro.2016.12.006
5. Đinh Công Định. “Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn III bằng hóa chất kết hợp xạ trị VMAT tại Bệnh viện K.” Luận văn thạc sĩ y học, Trường đại học Y Hà Nội.:2020.
6. Lê Thị Yến. Đánh giá kết quả hóa xạ trị đồng thời phác đồ paclitaxel - carboplatin trong ung thư phổi không tế bào nhỏ giai đoạn IIIB tại Bệnh viện K. Luận án tiến sĩ y học, Trường đại học Y Hà Nội. 2019.
7. Lê Tuấn Anh. “Hóa-xạ trị đồng thời ung thư phổi không tế bào nhỏ giai đoạn III.” Luận án tiến sĩ y học, Trường đại học Y Dược TP Hồ Chí Minh. Published online 2015.
8. Hàng Quốc Tuấn và cs. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn III không mổ được bằng phác đồ hóa chất Paclitaxel-Carboplatin kết hợp hóa xạ đồng thời . Tạp chí ung thư học Việt Nam, 4, 68-75. Published online 2020.
9. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013; 85(2):444-450. doi:10.1016/ j.ijrobp.2012.04.043